Bernstein said Novo Nordisk (NVO) study results that showed certain Rybelsus users had a 14% risk reduction for major ...

The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with T2D.

Novo Nordisk further stated that 49% of the enrolled patients received SGLT2i, the standard-of-care therapy, at some point ...

The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...

According to new data from the SOUL trial Oral semaglutide reduced MACE by 14% in Type 2 Diabetes patients. Novo Nordisk will ...

In Novo Nordisk’s randomized clinical trial, semaglutide reduced the risk for major adverse cardiovascular events by 14% ...

Teva Pharmaceuticals (NYSE:TEVA) on June 24, 2024, announced the authorized launch of a generic version of Novo Nordisk’s Victoza® as injected liraglutide and noted that Victoza had annual sales of $1 ...

In a phase III trial of adults with type 2 diabetes with heart disease and/or chronic kidney disease, oral semaglutide ...

Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings ...

The global Oral proteins and peptides market is projected to reach USD 7.38 billion in 2024 will increase to USD 20.36 billion by 2029, with ...

Oral semaglutide is currently approved under the brand name Rybelsus ® as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Based on these findings, ...

Semaglutide and tirzepatide helped Texas woman Kathryn Dean lose 18kg and keep the weight off, and she is no longer diagnosed ...